Residual platelet reactivity and outcomes with 5 mg prasugrel therapy in elderly patients undergoing percutaneous coronary intervention

International Journal of Cardiology

Volumn 176, Issue 3, 2014, Pages 874-877

  Parodi, Guido ^a,b   Bellandi, Benedetta ^a   Comito, Vincenzo ^a   Capodanno, Davide ^c   Valenti, Renato ^a   Marcucci, Rossella ^a,b   Carrabba, Nazario ^a   Migliorini, Angela ^a   Gensini, Gian Franco ^a,b,d   Abbate, Rosanna ^a,b   Antoniucci, David ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

Acute coronary syndrome; Bleeding; Elderly; Prasugrel; Stent

Indexed keywords

PIPERAZINE DERIVATIVE; PRASUGREL; PURINERGIC P2Y RECEPTOR ANTAGONIST; THIOPHENE DERIVATIVE;

ACUTE CORONARY SYNDROME; ADULT; AGE; AGED; BLOOD; DRUG EFFECTS; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PHYSIOLOGY; THROMBOCYTE; THROMBOCYTE ACTIVATION; TREATMENT OUTCOME; TRENDS; VERY ELDERLY;

ACUTE CORONARY SYNDROME; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BLOOD PLATELETS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PIPERAZINES; PLATELET ACTIVATION; PURINERGIC P2Y RECEPTOR ANTAGONISTS; THIOPHENES; TREATMENT OUTCOME;

EID: 84908258507     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.08.002     Document Type: Article

References (20)

1. K.P. Alexander, L.K. Newby, and C.P. Cannon Acute coronary care in the elderly, part I: non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology Circulation 115 2007 2549 2569
2. D. Capodanno, and D. Angiolillo Antithrombotic therapy in the elderly J Am Coll Cardiol 56 2010 1683 1692
3. S.D. Wiviott, E. Braunwald, and C.H. McCabe Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
4. H. Jneid, J.L. Anderson, and R.S. Wright A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update) Circulation 126 2012 875 910
5. P.G. Steg, S.K. James, and D. Atar ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Eur Heart J 33 2012 2569 2619
6. P.A. Gurbel, D. Erlinge, and E.M. Ohman Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy JAMA 308 2012 1785 1794
7. J. Silvain, G. Cayla, and J.S. Hulot High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study Eur Heart J 33 2012 1241 1249
8. D. Alexopoulos, I. Xanthopoulou, and T.E. Plakomyti Pharmacodynamic effect of prasugrel 5 mg vs clopidogrel 150 mg in elderly patients with high on-clopidogrel platelet reactivity Am Heart J 16 2013 73 79
9. D. Erlinge, P.A. Gurbel, and S. James Prasugrel 5-mg in the very elderly attenuates platelet inhibition but maintains non-inferiority to prasugrel 10-mg in non-elderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients J Am Coll Cardiol 62 2013 577 583
10. G. Parodi, B. Bellandi, and F. Venditti Residual platelet reactivity, bleedings and adherence to treatment in patients having coronary stent implantation treated with prasugrel Am J Cardiol 109 2012 214 218
11. G. Parodi, R. Marcucci, and R. Valenti Association between high residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing percutaneous coronary intervention JAMA 306 2011 1215 1223
12. T. Ciusset, J. Quilici, and C. Grosdidier Comparison of platelet reactivity and clopidogrel response in patients ≤ 75 years versus > 75 years undergoing percutaneous coronary interventions for non-ST elevation acute coronary syndrome Am J Cardiol 108 2011 1411 1416
13. R. Mehran, S.V. Rao, and D.L. Bhatt Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium Circulation 123 2011 2736 2747
14. D.E. Cutlip, S. Windecker, and R. Mehran Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
15. R.E. Wrishko, C.S. Ernest, and D.S. Small Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON - TIMI 38 J Clin Pharmacol 49 2009 984 998
16. European Medicines Agency for the evaluation of medicines for human use Doc. Ref.: EMEA/117561/2009 http://www.ema.europa.eu/docs/en-GB/document-library/EPARPublicassessmentreport
17. P. Capranzano, C. Tamburino, and D. Capodanno Platelet function profiles in the elderly: results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity Thromb Haemost 106 2011 1149 1157
18. D. Sibbing, S.R. Steinhubl, S. Schulz, A. Schömig, and A. Kastrati Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window J Am Coll Cardiol 56 2010 317 318
19. R. Mehran, S. Pocock, and E. Nikolsky Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials JACC Cardiovasc Interv 4 2011 654 664
20. W. Hochholzer, S.D. Wiviott, and E.M. Antman Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel - Thrombolysis in Myocardial Infarction 38 (TRITON - TIMI 38) Circulation 123 2011 2681 2689